21st Austria weekly - Valneva, Financial Market Authority (07/01/2021)

21st Austria weekly - Valneva Financial Market Authority 07/01/2021 [pic1]Valneva: Valnvea an Austrian/french specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need reported preliminary and unaudited cash equivalents Euro 204.4 mn at the end December 2020 exceeding its guidance between Euro180 200 mn. Valneva’s 31 2020 increased to compared 64.4 2019. The change was primarily driven by a USD 130.0 upfront payment related Lyme collaboration agreement Pfizer 96.7 UK COVID-19 partnership deal 48.8 net proceeds from financing arrangement Deerfield OrbiMed offset 20 repayments borrowings European